Outcomes in patients with < em > BRAF < /em > < sup > V600 < /sup > -mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib

CONCLUSIONS: Dabrafenib plus trametinib showed effectiveness in a real-world population of patients with advanced BRAFV600-mutated melanoma and BM at baseline, supporting its use in this population with poor outcomes.PMID:37417313 | DOI:10.1177/03008916231179251

Source: Tumori - July 7, 2023 Category: Cancer & Oncology Authors: Massimo Aglietta Vanna Chiarion-Sileni Paolo Fava Massimo Guidoboni Roberta Depenni Alessandro Minisini Francesca Consoli Paolo Antonio Ascierto Gaetana Rinaldi Maria Banzi Riccardo Marconcini Rossana Gueli Virginia Ferraresi Marco Tucci Giuseppe Tonini G Source Type: research